Celon Pharma S.A. (WSE:CLN)
Poland
· Delayed Price · Currency is PLN 21.90
-0.40 (-1.79%)
Jun 6, 2025, 9:44 AM CET
Celon Pharma Income Statement
Financials in millions PLN. Fiscal year is January - December.
Millions PLN. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 190.39 | 176.62 | 164.39 | 161.92 | 169.56 | 135.48 | Upgrade
|
| Other Revenue | 24.71 | 28.37 | 49.53 | 31.97 | 26.53 | 21.97 | Upgrade
|
| Revenue | 215.11 | 204.98 | 213.92 | 193.89 | 196.09 | 157.45 | Upgrade
|
| Revenue Growth (YoY) | 2.78% | -4.18% | 10.33% | -1.12% | 24.54% | 53.99% | Upgrade
|
| Cost of Revenue | 69.38 | 63.17 | 66.82 | 66.46 | 61.72 | 36.64 | Upgrade
|
| Gross Profit | 145.73 | 141.81 | 147.1 | 127.42 | 134.37 | 120.81 | Upgrade
|
| Selling, General & Admin | 123.86 | 120.04 | 111.12 | 107.7 | 90.11 | 83.44 | Upgrade
|
| Other Operating Expenses | 21.95 | 21.41 | 14.32 | 13.52 | 13.5 | 6.93 | Upgrade
|
| Operating Expenses | 199.65 | 194.75 | 175.46 | 165.32 | 144.96 | 124.91 | Upgrade
|
| Operating Income | -53.92 | -52.94 | -28.35 | -37.9 | -10.59 | -4.1 | Upgrade
|
| Interest Expense | -2.34 | -2.47 | -2.66 | -1.67 | -1.55 | -0.67 | Upgrade
|
| Interest & Investment Income | 0.3 | 0.16 | 0.37 | 1.85 | 0.08 | 0.14 | Upgrade
|
| Earnings From Equity Investments | -9.7 | -5.55 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.19 | -0.4 | 0.03 | -0.4 | -2.59 | -0.64 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.88 | 5.7 | 9.53 | 1.11 | -0.57 | -0.75 | Upgrade
|
| EBT Excluding Unusual Items | -62.97 | -55.49 | -21.08 | -37.01 | -15.22 | -6.02 | Upgrade
|
| Gain (Loss) on Sale of Investments | -2.28 | - | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.78 | 0.68 | 1.11 | 0.56 | 0.13 | 0.43 | Upgrade
|
| Asset Writedown | 15.45 | 15.45 | - | - | - | - | Upgrade
|
| Pretax Income | -49.02 | -39.37 | -19.97 | -36.45 | -15.09 | -5.59 | Upgrade
|
| Income Tax Expense | -5.16 | -4.92 | 8.16 | 2.83 | -3.48 | -4.67 | Upgrade
|
| Net Income | -43.86 | -34.45 | -28.12 | -39.28 | -11.61 | -0.92 | Upgrade
|
| Net Income to Common | -43.86 | -34.45 | -28.12 | -39.28 | -11.61 | -0.92 | Upgrade
|
| Shares Outstanding (Basic) | 53 | 53 | 51 | 51 | 47 | 45 | Upgrade
|
| Shares Outstanding (Diluted) | 53 | 53 | 51 | 51 | 47 | 45 | Upgrade
|
| Shares Change (YoY) | 4.01% | 2.86% | 0.04% | 9.32% | 3.74% | - | Upgrade
|
| EPS (Basic) | -0.83 | -0.66 | -0.55 | -0.77 | -0.25 | -0.02 | Upgrade
|
| EPS (Diluted) | -0.83 | -0.66 | -0.55 | -0.77 | -0.25 | -0.02 | Upgrade
|
| Free Cash Flow | -43.15 | -34.13 | -41.13 | -38.61 | 2.6 | -27.74 | Upgrade
|
| Free Cash Flow Per Share | -0.81 | -0.65 | -0.81 | -0.76 | 0.06 | -0.62 | Upgrade
|
| Dividend Per Share | - | - | 0.080 | 0.090 | 0.290 | 0.070 | Upgrade
|
| Dividend Growth | - | - | -11.11% | -68.97% | 314.29% | -12.50% | Upgrade
|
| Gross Margin | 67.75% | 69.18% | 68.77% | 65.72% | 68.53% | 76.73% | Upgrade
|
| Operating Margin | -25.07% | -25.82% | -13.25% | -19.55% | -5.40% | -2.60% | Upgrade
|
| Profit Margin | -20.39% | -16.80% | -13.15% | -20.26% | -5.92% | -0.58% | Upgrade
|
| Free Cash Flow Margin | -20.06% | -16.65% | -19.23% | -19.91% | 1.33% | -17.62% | Upgrade
|
| EBITDA | -19.09 | -14.97 | 8.63 | -2.57 | 27.84 | 25.49 | Upgrade
|
| EBITDA Margin | -8.88% | -7.31% | 4.04% | -1.33% | 14.20% | 16.19% | Upgrade
|
| D&A For EBITDA | 34.83 | 37.96 | 36.99 | 35.33 | 38.43 | 29.59 | Upgrade
|
| EBIT | -53.92 | -52.94 | -28.35 | -37.9 | -10.59 | -4.1 | Upgrade
|
| EBIT Margin | -25.07% | -25.82% | -13.25% | -19.55% | -5.40% | -2.60% | Upgrade
|
| Revenue as Reported | 216.19 | 207.19 | 216.57 | 194.59 | 199.11 | 159.99 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.